Hyprevention Inc.

Hyprevention Inc. develops and markets STRUTPLASTY®, a proprietary technology for reinforcing bones weakened by osteoporosis or cancer-related fractures. The company manufactures implantable devices combining PEEK (polyetheretherketone)—a biocompatible polymer with stiffness properties approximating natural bone—with PMMA bone cement. These implants are designed for fracture treatment and fracture prevention in compromised bone. The company operates through a dual-center model: Hyprevention Inc. (USA headquarters in New York) and Hyprevention SAS (R&D and operations in Pessac, France). Products are distributed internationally via regional partners in Brazil, Mexico, Colombia, Middle East & Africa, and Jordan. The company actively participates in clinical research and medical society conferences (ASSR, SIR, ASPN), with peer-reviewed publications demonstrating clinical outcomes. Hyprevention pairs in-house research capabilities with external clinical expertise to develop solutions addressing vertebral compression fractures and bone reinforcement in osteoporotic and oncologic populations.